Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

by dyadic | Aug 11, 2021 | Press Releases

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic...

Dyadic to Report Second Quarter 2021 Financial Results

by dyadic | Jul 29, 2021 | Press Releases

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

by dyadic | Jul 27, 2021 | Press Releases

Potential for Affordable COVID-19 Immunization Coverage in Underserved African CountriesArrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through...

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

by dyadic | Jun 28, 2021 | Press Releases

Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1...

Dyadic announces development of COVID-19 Vaccine in India

by dyadic | May 26, 2021 | Press Releases

In collaboration with Syngene International Ltd.JUPITER, Fla., May 26, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying...